Ibrutinib for Chronic Lymphocytic Leukemia with TP53 Alterations.

doi:10.1056/nejmc2005943

PMID: 32726539DOI: 10.1056/nejmc2005943Jul 30, 2020Paper

Ibrutinib for Chronic Lymphocytic Leukemia with TP53 Alterations.

The New England Journal of Medicine

Inhye E AhnAdrian Wiestner

Get PDF

Abstract

No abstract listed.

References

Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study

Sep 18, 2016·The Lancet Oncology·Susan O'BrienStephan Stilgenbauer

Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study.

Feb 28, 2018·Blood·Inhye E AhnAdrian Wiestner

Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL

Dec 7, 2018·The New England Journal of Medicine·Jennifer A WoyachJohn C Byrd

Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions

Jun 6, 2019·The New England Journal of Medicine·Kirsten FischerMichael Hallek

Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.

Aug 1, 2019·The New England Journal of Medicine·Tait D ShanafeltMartin Tallman

❮ Previous

Next ❯

Citations

Chemotherapy-free frontline therapy for CLL: is it worth it?

Dec 5, 2020·Hematology·Joanna M Rhodes, Jacqueline C Barrientos

Incorporating molecular biomarkers into the continuum of care in chronic lymphocytic leukemia.

Jan 8, 2021·Leukemia & Lymphoma·Paul J HampelTimothy G Call

Overcoming resistance to targeted therapies in chronic lymphocytic leukemia.

Feb 12, 2021·Blood Advances·Sigrid S Skånland, Anthony R Mato

Risk-adapted, ofatumumab-based chemoimmunotherapy and consolidation in treatment-naïve chronic lymphocytic leukemia: a phase 2 study.

Mar 4, 2021·Leukemia & Lymphoma·Sanjal DesaiInhye E Ahn

Comparison Between Venetoclax-based and Bruton Tyrosine Kinase Inhibitor-based Therapy as Upfront Treatment of Chronic Lymphocytic Leukemia (CLL): A Systematic Review and Network Meta-analysis.

Nov 18, 2020·Clinical Lymphoma, Myeloma & Leukemia·Stefano MolicaEmili Montserrat

From Biomarkers to Models in the Changing Landscape of Chronic Lymphocytic Leukemia: Evolve or Become Extinct.

May 1, 2021·Cancers·Isabel González-Gascón-Y-MarínJosé-Ángel Hernández-Rivas

Chemoimmunotherapy in the First-Line Treatment of Chronic Lymphocytic Leukaemia: Dead Yet, or Alive and Kicking?

Jul 3, 2021·Cancers·Lukáš SmolejMartin Šimkovič

First-Line Therapy for Chronic Lymphocytic Leukemia: Bruton Tyrosine Kinase or BCL2 or Both?

Jun 28, 2021·Hematology/oncology Clinics of North America·Hua-Jay J Cherng, Nitin Jain

The Ongoing Unmet Needs in Chronic Lymphocytic Leukemia: TP53 Disruption, Richter, and Beyond.

Jun 28, 2021·Hematology/oncology Clinics of North America·Wei Ding

Treatment of Chronic Lymphocytic Leukemia After Discontinuation of Bruton's Tyrosine Kinase Inhibitors.

Jun 28, 2021·Hematology/oncology Clinics of North America·Meghan C Thompson, Anthony R Mato

Immune Therapy for Chronic Lymphocytic Leukemia: Allogeneic Transplant, Chimeric Antigen Receptor T-cell Therapy, and Beyond.

Jun 28, 2021·Hematology/oncology Clinics of North America·Mazyar Shadman, David G Maloney

Targeting Bruton's Tyrosine Kinase in CLL.

Jul 13, 2021·Frontiers in Immunology·Inhye E Ahn, Jennifer R Brown

Significance of Tumor Mutation Burden Combined With Immune Infiltrates in the Progression and Prognosis of Advanced Gastric Cancer.

Jul 27, 2021·Frontiers in Genetics·Xiong GuoZiwei Wang

Second-Generation Bruton's Tyrosine Kinase Inhibitors: Simply the Best Treatments for Chronic Lymphocytic Leukemia?

Jul 27, 2021·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Deborah M Stephens

Clinical Outcomes in Patients with Multi-Hit TP53 Chronic Lymphocytic Leukemia Treated with Ibrutinib.

May 9, 2021·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Christian BrieghelCarsten U Niemann

The Biology of Chronic Lymphocytic Leukemia: Diagnostic and Prognostic Implications.

Aug 17, 2021·The Cancer Journal·Riccardo MoiaGianluca Gaidano

Integrating New Therapies for Chronic Lymphocytic Leukemia.

Aug 17, 2021·The Cancer Journal·Jan A Burger

Is There a Role for Cellular Therapy in Chronic Lymphocytic Leukemia?

Aug 17, 2021·The Cancer Journal·Peter Dreger

Resistance to Bruton tyrosine kinase inhibitors: the Achilles heel of their success story in lymphoid malignancies.

Jul 29, 2021·Blood·Deborah M Stephens, John C Byrd

BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19/CD3-bispecific antibody in CLL.

May 29, 2021·Blood·Maissa MhibikAdrian Wiestner

Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations.

Jun 5, 2021·Blood·Paula CramerMichael Hallek

Improving the outlook for TP53-aberrant CLL.

Nov 12, 2021·Blood·Michael Y Choi

Treatment strategies for a rapidly evolving landscape in chronic lymphocytic leukemia management.

Oct 30, 2021·Hematological Oncology·Toby A EyreTalha Munir

Acalabrutinib: Nursing Considerations for Use in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma.

Nov 21, 2021·Clinical Journal of Oncology Nursing·Pia Nierman

Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures.

Oct 10, 2021·American Journal of Hematology·Michael Hallek, Othman Al-Sawaf

Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials.

Dec 6, 2021·British Journal of Haematology·John N AllanInhye E Ahn

Upfront therapy: the case for continuous treatment.

Dec 11, 2021·Hematology·Constantine S Tam

Ibrutinib induces durable remissions in treatment-naïve patients with CLL and 17p deletion and/or TP53 mutations.

Sep 15, 2021·Blood·Mariela SivinaJan A Burger

Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia: A real-life campus CLL study.

Dec 15, 2021·American Journal of Hematology·Andrea VisentinLivio Trentin

Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies.

Jan 12, 2022·Leukemia & Lymphoma·Jan A BurgerAlessandra Tedeschi

Is BTKi or BCL2i preferable as first novel therapy in patients with CLL? The case for BCL2i.

Dec 30, 2021·Blood Advances·John F Seymour

❮ Previous

Next ❯

Related Concepts

Related Feeds

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Ibrutinib for Chronic Lymphocytic Leukemia with TP53 Alterations.

Abstract

References

Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study

Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study.

Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL

Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions

Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.

Citations

Chemotherapy-free frontline therapy for CLL: is it worth it?

Incorporating molecular biomarkers into the continuum of care in chronic lymphocytic leukemia.

Overcoming resistance to targeted therapies in chronic lymphocytic leukemia.

Risk-adapted, ofatumumab-based chemoimmunotherapy and consolidation in treatment-naïve chronic lymphocytic leukemia: a phase 2 study.

Comparison Between Venetoclax-based and Bruton Tyrosine Kinase Inhibitor-based Therapy as Upfront Treatment of Chronic Lymphocytic Leukemia (CLL): A Systematic Review and Network Meta-analysis.

From Biomarkers to Models in the Changing Landscape of Chronic Lymphocytic Leukemia: Evolve or Become Extinct.

Chemoimmunotherapy in the First-Line Treatment of Chronic Lymphocytic Leukaemia: Dead Yet, or Alive and Kicking?

First-Line Therapy for Chronic Lymphocytic Leukemia: Bruton Tyrosine Kinase or BCL2 or Both?

The Ongoing Unmet Needs in Chronic Lymphocytic Leukemia: TP53 Disruption, Richter, and Beyond.

Treatment of Chronic Lymphocytic Leukemia After Discontinuation of Bruton's Tyrosine Kinase Inhibitors.

Immune Therapy for Chronic Lymphocytic Leukemia: Allogeneic Transplant, Chimeric Antigen Receptor T-cell Therapy, and Beyond.

Targeting Bruton's Tyrosine Kinase in CLL.

Significance of Tumor Mutation Burden Combined With Immune Infiltrates in the Progression and Prognosis of Advanced Gastric Cancer.

Second-Generation Bruton's Tyrosine Kinase Inhibitors: Simply the Best Treatments for Chronic Lymphocytic Leukemia?

Clinical Outcomes in Patients with Multi-Hit TP53 Chronic Lymphocytic Leukemia Treated with Ibrutinib.

The Biology of Chronic Lymphocytic Leukemia: Diagnostic and Prognostic Implications.

Integrating New Therapies for Chronic Lymphocytic Leukemia.

Is There a Role for Cellular Therapy in Chronic Lymphocytic Leukemia?

Resistance to Bruton tyrosine kinase inhibitors: the Achilles heel of their success story in lymphoid malignancies.

BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19/CD3-bispecific antibody in CLL.

Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations.

Improving the outlook for TP53-aberrant CLL.

Treatment strategies for a rapidly evolving landscape in chronic lymphocytic leukemia management.

Acalabrutinib: Nursing Considerations for Use in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma.

Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures.

Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials.

Upfront therapy: the case for continuous treatment.

Ibrutinib induces durable remissions in treatment-naïve patients with CLL and 17p deletion and/or TP53 mutations.

Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia: A real-life campus CLL study.

Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies.

Is BTKi or BCL2i preferable as first novel therapy in patients with CLL? The case for BCL2i.

Related Concepts

Related Feeds

B-Cell Leukemia (Keystone)

Related Papers

Ibrutinib for Chronic Lymphocytic Leukemia

Ibrutinib for Chronic Lymphocytic Leukemia

Ibrutinib for Chronic Lymphocytic Leukemia

Ibrutinib for Chronic Lymphocytic Leukemia

The use of ibrutinib in chronic lymphocytic leukemia